Impact of coronavirus disease 2019 on medical practice in endocrine and metabolic diseases in Japan: a nationwide surveillance study conducted by the Japan Endocrine Society
-
- Manaka Katsunori
- Department of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan
-
- Kato Sayaka
- Department of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
-
- Sakamoto Ryuichi
- Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
-
- Yamakage Hajime
- Department of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
-
- Uema Tsugumi
- Second Department of Internal Medicine (Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology), Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0213, Japan
-
- Kawai Shiori
- Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, Japan
-
- Shibata Megumi
- Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, School of Medicine, Aichi 470-1192, Japan
-
- Hiratsuka Izumi
- Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, School of Medicine, Aichi 470-1192, Japan
-
- Nakachi Sawako
- Second Department of Internal Medicine (Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology), Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0213, Japan
-
- Onoue Takeshi
- Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Aichi 466-8550, Japan
-
- Tsuchiya Takefumi
- Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, Japan
-
- Fukui Michiaki
- Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
-
- Hashimoto Koshi
- Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, Japan
-
- Suzuki Atsushi
- Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, School of Medicine, Aichi 470-1192, Japan
-
- Makita Noriko
- Department of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan
-
- Ogawa Yoshihiro
- Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
-
- Arima Hiroshi
- Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Aichi 466-8550, Japan
-
- Satoh-Asahara Noriko
- Department of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan Department of Metabolic Syndrome and Nutritional Science, Research Institute of Environmental Medicine, Nagoya University, Aichi 466-8550, Japan
-
- Masuzaki Hiroaki
- Second Department of Internal Medicine (Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology), Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0213, Japan
説明
<p>We investigated the impact of the Coronavirus disease 2019 (COVID-19) pandemic on the management of endocrine and metabolic disorders in Japan. We conducted a cross-sectional nationwide questionnaire survey targeting board-certified endocrinologists under the auspices of the Japan Endocrine Society. The questionnaire consisted of multiple-choice questions and open-ended responses. Out of approximately 2,700 specialists, 528 (19.5%) opted to participate, suggesting a high level of interest in COVID-19 management among endocrinologists. The study found that almost half of participants had encountered cases of endocrine and metabolic disorders following COVID-19 infection or vaccination. Conditions related to thyroid diseases, glucose metabolism disorders/diabetes, and hypothalamic-pituitary disorders were particularly prevalent. Diabetes and obesity were identified as having high rates of severe cases or fatalities due to COVID-19. The study also highlighted challenges in routine diagnosis and treatment, emphasizing the potential benefits of combining remote consultations with in-person visits to optimize the frequency of examinations and check-ups during infectious disease outbreak which disrupts access to healthcare providers. The insights obtained from this survey are expected to contribute to ensuring appropriate healthcare provision for patients with endocrine and metabolic disorders by using flexible consultation formats, particularly even in the conditions where medical access may be limited due to future outbreaks of emerging or re-emerging infectious diseases.</p>
収録刊行物
-
- Endocrine Journal
-
Endocrine Journal 71 (5), 499-514, 2024
一般社団法人 日本内分泌学会